Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
Recruiting · Phase 1 · NCT05195710
Conditions: Metastases
At a glance
- Research payments reported, 2025
- $54,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 50
About the trial
- Sponsor
- M.D. Anderson Cancer Center (with Sirtex Medical)
- Tested
- Yttrium-90 (Y-90) resin microspheres (drug)
- Dates
- Started 2022-11-16; completion 2028-03-31
- Results posted
- Not yet
A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM and insufficient FLR at the time of presentation.
From ClinicalTrials.gov, last updated 2026-05-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sirtex Medical Inc reported $54,000 in research payments for this study in 2025 (2 payments).
Products named: Sir-Spheres Microspheres
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $54,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.